New Hope for RDEB? INmune Bio to Unveil Pivotal Phase III Data

BOCA RATON, FL – February 19, 2026 – In a move closely watched by patients, clinicians, and investors, late-stage biotechnology firm INmune Bio Inc. (NASDAQ: INMB) announced it will host a webinar on February 26 to present new data from its pivotal Phase III trial for CORDStrom™, a novel cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The announcement sets the stage for a potentially transformative moment for a community grappling with a devastating rare disease that has long lacked effective systemic treatments.

For thousands of children and adults living with RDEB, life is a cycle of chronic pain, debilitating wounds, and systemic complications. The upcoming webinar promises a first look at comprehensive results from the MissionEB clinical study, which evaluated CORDStrom™ not as a topical bandage, but as a systemic, disease-modifying therapy. The presentation will feature insights from the trial's principal investigator, Dr. Anna Martinez, a leading UK specialist in pediatric RDEB, and INmune Bio's Chief Scientific Officer, Prof. Mark Lowdell.

Beyond Skin Deep: A Systemic Approach to a Devastating Disease

RDEB is a brutal genetic disorder characterized by extremely fragile skin that blisters and tears from the slightest friction. Caused by a faulty gene that prevents the production of functional collagen VII—the protein that anchors the layers of the skin together—the disease leads to chronic, non-healing wounds, severe scarring, and debilitating pain and itch. Its impact is not merely skin-deep; patients often suffer from systemic complications including anemia, joint contractures, and severe malnutrition, a condition often termed “failure to thrive” in pediatric patients.

For decades, the standard of care has been limited to supportive measures: meticulous, painful daily wound dressing changes and topical treatments that offer symptomatic relief but do not alter the disease's relentless progression. INmune Bio aims to shatter this paradigm with CORDStrom™. The company’s upcoming presentation will focus on data points that underscore a systemic impact, moving far beyond localized wound care. Key metrics to be revealed include changes in the EB Disease Activity and Scarring Index (EBDASI), a crucial measure of skin improvement.

Perhaps most importantly for families, the company will present evidence of nutritional improvement and weight gain in children, directly addressing the systemic inflammation and gastrointestinal issues that plague young patients. Furthermore, the webinar will detail reductions in pain and itch—two of the most significant drivers of morbidity and poor quality of life—along with feedback from investigators on functional improvements in patients' daily lives.

The Science of CORDStrom: An "Off-the-Shelf" Cellular Medicine

At the heart of INmune Bio’s approach is CORDStrom™, a patent-pending cell therapy derived from pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs). Unlike autologous therapies that require harvesting a patient's own cells for modification, CORDStrom™ is an allogeneic, or “off-the-shelf,” product. This allows for the creation of consistent, scalable, and more affordable batches of cellular medicine ready for infusion.

Mesenchymal stromal cells are known for their powerful regenerative and immunomodulatory properties. When administered systemically, they have the ability to home in on sites of injury and inflammation. Once there, they release a cascade of factors that can reduce inflammation, combat fibrosis (scarring), and promote the body's natural healing processes. For RDEB patients, this could mean not only improved wound healing but also a reduction in the systemic inflammation that drives many of the disease's most severe complications.

According to the company, its proprietary platform allows for the screening and pooling of donor cells to create products optimized for specific functions like anti-inflammatory or wound-healing activity. This scientific rationale, which will be detailed by Prof. Mark Lowdell, underpins the hope that CORDStrom™ can provide a holistic treatment that addresses the root causes of suffering in RDEB.

High Stakes in a Shifting Landscape

The data release comes at a critical juncture for INmune Bio. The company’s stock (NASDAQ: INMB) has traded near its 52-week low, reflecting a challenging market for small-cap biotech and the inherent risk of clinical development. With a market capitalization hovering under $40 million and a reported cash runway projected to last until late 2026, the company is under immense pressure to deliver positive results. A successful Phase III outcome could dramatically alter its trajectory, validating its CORDStrom™ platform and potentially sending its valuation soaring.

The competitive landscape for RDEB has also evolved significantly in recent years. In 2023, Krystal Biotech’s Vyjuvek, a topical, redosable gene therapy, gained FDA approval. More recently, in 2025, Abeona Therapeutics received approval for Zevaskyn, an autologous, gene-modified cell therapy applied as a skin sheet to chronic wounds. While these approvals represent major victories for patients, they are primarily localized treatments.

This is where INmune Bio sees its unique advantage. CORDStrom™ is one of the few therapies in late-stage development designed to treat the entire body systemically. Its allogeneic nature also distinguishes it from complex and costly autologous procedures. If the MissionEB data demonstrates significant and durable systemic benefits, CORDStrom™ could carve out a vital and complementary role in the RDEB treatment arsenal, offering a solution for the widespread, internal effects of the disease that topical therapies cannot reach. All eyes in the rare disease community will be on the company's webinar on February 26, an event that could mark the dawn of a new therapeutic era for RDEB patients.